Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hadley, S.
Right arrow Articles by Snydman, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hadley, S.
Right arrow Articles by Snydman, D. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2002) 49, 415-419
© 2002 The British Society for Antimicrobial Chemotherapy

Brief report

Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients

Susan Hadleya,*, José A. Martinezb, Laura McDermotta, Barbara Rapinoa and David R. Snydmana

a Department of Medicine, Division of Geographic Medicine and Infectious Diseases, New England Medical Center, Box 041, Tufts University School of Medicine, 750 Washington Street, Boston, MA 02111, USA; b The Infectious Diseases Unit, Hospital Clinic of Barcelona, Barcelona, Spain

We examined the utility of a semi-solid agar antifungal susceptibility screening (SAAS) test in real-time management of eight immunocompromised patients with invasive yeast infections. Tests of amphotericin B and fluconazole concentrations of 0.5 and 2 mg/L and 1, 8 and 40 mg/L, respectively, were performed on Candida albicans (two), Candida tropicalis (two), Candida krusei (one), Candida glabrata (one) and Trichosporon species (spp.) (two). All but the Trichosporon spp. and C. glabrata isolates were resistant to fluconazole at 40 mg/L, and patients were successfully managed accordingly. Real-time antifungal susceptibility screening can assist in clinical management of invasive yeast infections.

* Corresponding author. Tel: +1-617-636-1567; Fax: +1-617-636-8525; E-mail: shadley{at}lifespan.org


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
M. A. Pfaller, D. J. Diekema, M. A. Ghannoum, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, A. Espinel-Ingroff, C. L. Fowler, et al.
Wild-Type MIC Distribution and Epidemiological Cutoff Values for Aspergillus fumigatus and Three Triazoles as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Methods
J. Clin. Microbiol., October 1, 2009; 47(10): 3142 - 3146.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
M. A. Pfaller, L. B. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar, and D. J. Diekema
Validation of 24-Hour Fluconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Results from a Global Candida Antifungal Surveillance Program
J. Clin. Microbiol., November 1, 2008; 46(11): 3585 - 3590.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
C. D. Collins, G. A. Eschenauer, S. L. Salo, and D. W. Newton
To Test or Not To Test: a Cost Minimization Analysis of Susceptibility Testing for Patients with Documented Candida glabrata Fungemias
J. Clin. Microbiol., June 1, 2007; 45(6): 1884 - 1888.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
M. A. Pfaller and D. J. Diekema
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Clin. Microbiol. Rev., January 1, 2007; 20(1): 133 - 163.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
M. A. Pfaller, D. J. Diekema, and D. J. Sheehan
Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing
Clin. Microbiol. Rev., April 1, 2006; 19(2): 435 - 447.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
C. Kuzucu, B. Rapino, L. McDermott, and S. Hadley
Comparison of the Semisolid Agar Antifungal Susceptibility Test with the NCCLS M38-P Broth Microdilution Test for Screening of Filamentous Fungi
J. Clin. Microbiol., March 1, 2004; 42(3): 1224 - 1227.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
S. M. Nelson and C. P. Cartwright
Detection of Fluconazole-Resistant Isolates of Candida glabrata by Using an Agar Screen Assay
J. Clin. Microbiol., May 1, 2003; 41(5): 2141 - 2143.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.